Peanut Allergy: Opportunity Analysis and Forecasts to 2027

Peanut allergy is defined as a harmful health effect resulting from a specific and reproducible immune response following the ingestion of peanuts. While exposure to dietary antigens within the gastro-intestinal tract normally leads to oral tolerance, in certain individuals this mechanism fails. This results in sensitization and subsequent allergic responses towards innocuous food antigens. The most dangerous of these responses is an acute systemic reaction called anaphylaxis.

Peanut allergy has prevalence of 1-2.5% in developed nations and a low rate of remission—only around 20% in children. Though the specific etiology of peanut allergy is unclear, it is likely due to the interaction of genetic predisposition with environmental factors . Currently the only available strategy for managing peanut allergy long-term is avoidance and the treatment of acute reactions with injectable epinephrine. Some physicians have begun to offer their patients an investigational treatment known as experimental peanut oral immunotherapy. Though these grassroots efforts can be effective in desensitizing patients to peanut, they lack standardization and regulatory agency approval, thus making it difficult to ensure the safety of the treatment. With a complete absence of approved therapies available, peanut allergy is an indication with extremely high unmet need.

GlobalData projects the global peanut allergy marketplace — which, for the purposes of this report, comprises eight major pharmaceutical markets (US, France, Germany, Italy, Spain, UK, Canada, and Australia) — to experience intense growth during the forecast period. GlobalData forecasts the peanut allergy market to grow over 1,700-fold between 2017 and 2027. This incredible growth stems from the projected entry of four new peanut immunotherapy products into a previously empty marketplace. These new therapies include three oral immunotherapy (OIT) products—Aimmune Therapeutics’ AR-101, Prota Therapeutics’ PPOIT, and Camallergy’s CA-002—and one epicutaneous immunotherapy product—DBV Technologies’ Viaskin Peanut.

Growing at a compound annual growth rate (CAGR) of 111% over the 10-year forecast period, in 2027 peanut allergy sales are projected to reach over $4.5 billion. The majority of sales (88%) will come from the US. This is mainly due to the US having a large population of potential patients (estimated 3,000,000 probable diagnosed prevalent cases), an elevated expected price tag for new therapies (nearly 5-7 times that of the other geographies), and a higher expected treatment rate (based on good accessibility to allergy specialists).

Aimmune’s AR-101, is expected to be the market leader among the four peanut immunotherapy products released during the forecast, period, capturing over 67% of the peanut allergy market in 2027, worth an estimated $3.0B. Second in sales is DBV Technologies’ Viaskin Peanut, which is projected to capture 32% of the peanut allergy market in 2027, totaling nearly $1.4B in sales. Finally, sales for Prota Therapeutics’ and Camallergy’s products, PPOIT and CA-002, together are only expected to total 1%. This estimate is based on GlobalData’s assumption that within the forecast period these therapies will each only be released in one geography—Australia and the 5EU respectively.

Key Questions Answered

The projected entry of four new peanut immunotherapy products during the forecast period is expected to spur intense growth within the peanut allergy market. How are these immunotherapy products similar and different? What are the strengths and weaknesses of the small biotech and start-up companies launching these therapies? Which of these drugs will have the highest peak sales, and why?

Key Opinion Leaders (KOLs) interviewed by GlobalData have indicated that there are considerably high unmet needs within the peanut allergy indication. What are the main unmet needs in this market? How can the pharmaceutical industry address these needs? To what degree will the therapies under development fulfill these unmet needs?

The peanut allergy market is likely to remain a dynamic, growing space throughout the forecast period and beyond. What are the main R&D trends in this market and which companies are leading the way? Are there major differences in the mechanisms of action used by therapies in late-stage versus early stage clinical development?

Scope

Overview of peanut allergy including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Annualized peanut allergy therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2017 and forecast for ten years to 2027.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the peanut allergy therapeutics market.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Analysis of the current and future market competition in the global peanut allergy therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.

Develop business strategies by understanding the trends shaping and driving the global peanut allergy therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global peanut allergy therapeutics market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track drug sales in the global peanut allergy therapeutics market from 2017-2027.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Companies mentioned

Aimmune Therapeutics

DBV Technologies

Prota Therapeutics

Cambridge Allergy

Sanofi

Regeneron

AnaptysBio

Mylan

ALK Abello

Stallargenes Greer

Astellas Pharma

Immunomic Therapeutics

HAL Allergy

Aravax

Immune Design ...

Aimmune Therapeutics

DBV Technologies

Prota Therapeutics

Cambridge Allergy

Sanofi

Regeneron

AnaptysBio

Mylan

ALK Abello

Stallargenes Greer

Astellas Pharma

Immunomic Therapeutics

HAL Allergy

Aravax

Immune Design

ASIT Biotech

Allakos

BioLingus

Allergy Therapeutics

Sementis

Selecta Biosciences.

Intrommune Therapeutics

Adverum Biotechnologies

Virtici

Alfacyte

Perosphere

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Peanut Allergy: Executive Summary

2.1 Intense Growth Expected for ...

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Peanut Allergy: Executive Summary

2.1 Intense Growth Expected for Peanut Allergy Market Following Launch of First-in-Class Targeted Therapies

2.2 The Peanut Allergy Market is Currently Dominated by Small Biotech and Start-Up Companies Using Immunotherapies to Desensitize Patients to Peanut

2.3 Vast Unmet Needs Exist in the Peanut Allergy Market

2.4 Abundant Opportunities Remain for New Entrants to Improve Upon and Transform Therapeutic Options for Peanut Allergy

2.5 Launches of Novel Pipeline Products Will Revolutionize the Peanut Allergy Treatment Landscape and Generate Significant Sales

2.6 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Symptoms

4.3 Prognosis and Quality of Life

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for Peanut Allergy (2017–2027)

5.5.1 Probable Diagnosed Prevalent Cases of Peanut Allergy

5.5.2 Age-Specific Probable Diagnosed Prevalent Cases of Peanut Allergy

5.5.3 Sex-Specific Diagnosed Prevalent Cases of Peanut Allergy

5.5.4 Probable Diagnosed Prevalent Cases of Peanut Allergy with Comorbid Condition

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of Analysis

5.6.3 Strengths of Analysis

6 Current Treatment Options

6.1 Overview

6.2 Diagnosis

6.3 Treatment

6.3.1 Guidelines

6.3.2 Avoidance and Prevention

6.3.3 Acute Reactions

6.3.4 Peanut Desensitization Using Experimental Oral Immunotherapy

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Therapies Promoting Permanent Tolerance to Peanut

7.3 Biomarkers to Improve Diagnostic Sensitivity and Better Evaluate Patient Responses to Treatment

7.3.1 Improved Diagnostic Sensitivity

7.3.2 Biomarkers to Better Evaluate Patient Responses to Immunotherapy Treatment

7.4 Strategies to Minimize Side Effects in Immunotherapy Protocols

7.5 Strategies to Ensure Long-Term Compliance in Immunotherapy Protocols

7.6 Increased Access to Allergy Specialists

7.7 Enhanced Educational and Allergy Management Resources for a Broad Range of Audiences

8 R&D Strategies

8.1 Overview

8.1.1 Peanut Immunotherapies

8.1.2 Immuno-modulating Biologics Targeting Multiple Allergic Diseases

8.2 Clinical Trials Design

8.2.1 Current Clinical Trial Design

8.2.2 Biomarkers: Limitations and Future Outlook

8.2.3 Trial Design for Real-World Applicability

9 Pipeline Assessment

9.1 Overview

9.2 Innovative Early-Stage Approaches

9.3 Other Drugs in Development

10 Pipeline Valuation Analysis

10.1 Clinical Benchmark of Key Pipeline Drugs

10.2 Commercial Benchmark of Key Pipeline Drugs

10.3 Competitive Assessment

10.4 Top-Line 10-Year Forecast

10.4.1 US

10.4.2 5EU

10.4.3 Canada

10.4.4 Australia

11 Appendix

11.1 Bibliography

11.2 Abbreviations

11.3 Methodology

11.3.1 Forecasting Methodology

11.3.2 Diagnosed Patients

11.3.3 Drug Treated Population for Peanut Allergy

11.3.4 Drugs Included in Each Therapeutic Class

11.3.5 Launch and Patent Expiry Dates

11.3.6 General Pricing Assumptions

11.3.7 Individual Drug Assumptions

11.3.8 Pricing of Pipeline Agents

11.4 Primary Research – KOLs Interviewed for This Report

11.4.1 KOLs

11.4.2 Payers

11.4.3 Community Allergists

11.5 Primary Research – Prescriber Survey

11.6 About the Authors

11.6.1 Analyst

11.6.2 Therapy Area Director

11.6.3 Epidemiologist

11.6.4 Epidemiology Reviewers

11.6.5 Global Director of Therapy Analysis and Epidemiology

11.6.6 Global Head and EVP of Healthcare Operations and Strategy

11.7 About GlobalData

11.8 Contact Us

11.9 Disclaimer

List of Tables

Table 1: Peanut Allergy: Key Metrics in the 8MM, 2017–2027

Table 2: Symptoms of Peanut-Induced Allergic Reactions

Table 3: Risk Factors and Comorbidities for ...

Table 1: Peanut Allergy: Key Metrics in the 8MM, 2017–2027

Table 2: Symptoms of Peanut-Induced Allergic Reactions

Table 3: Risk Factors and Comorbidities for Peanut Allergy

Table 4: SPT and sIgE Cutoffs for Peanut Allergy Diagnosis

Table 5: Popular Guidelines Available for Peanut Allergy, 2017

Table 6: Clinical Criteria for Diagnosing Anaphylaxis

Table 7: Pharmacologic Management of Anaphylaxis

Table 8: Comparative Assessment of Peanut Immunotherapy Strategies, 2017

Table 9: Clinical Trial Design for Key Immunotherapy Pipeline Agents in Late-stage Development, 2017

Table 10: Comparison of Therapeutic Classes in Late-stage Development for Peanut Allergy

Table 11: Innovative Early-Stage Approaches for Peanut Allergy, 2017

Table 12: Other Drugs in Development for Peanut Allergy, 2017

Table 13: Clinical Benchmark of Key Pipeline Drugs – Peanut Allergy, 2017

Table 14: Commercial Benchmark of Key Pipeline Drugs – Peanut Allergy, 2017

Table 15: Key Events Impacting Sales for Peanut Allergy, 2017–2027

Table 16: Peanut Allergy Market – Global Drivers and Barriers, 2017–2027

Table 17: Key Projected Launch Dates for Peanut Allergy, 2017–2027

Table 18: Key Projected Patent Expiry Dates for Peanut Allergy, 2017–2027

Table 19: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

Figure 1: Global (8MM) Sales Forecast by Geography for Peanut Allergy in 2017 and 2027

Figure 2: Competitive Assessment of Pipeline Drugs Benchmarked Against the ...

Figure 1: Global (8MM) Sales Forecast by Geography for Peanut Allergy in 2017 and 2027

Figure 2: Competitive Assessment of Pipeline Drugs Benchmarked Against the SOC, Experimental Peanut OIT, 2017–2027

Figure 3: Hypersensitivity Reaction to Peanut Allergen and Therapeutic Targets

Figure 4: Sensitization to Peanut Allergen and Therapeutic Targets

Figure 5: 8MM, Age-Standardized Probable Diagnosed Prevalence of Peanut Allergy, All Ages, 2017

Figure 6: 8MM, Sources Used and Not Used to Forecast the Probable Diagnosed Prevalent Cases of Peanut Allergy

Figure 7: 8MM, Sources Used to Forecast the Probable Diagnosed Prevalent Cases of Peanut Allergy with Comorbidity of Asthma and AD

Figure 8: 8MM, Sources Used to Forecast the Probable Diagnosed Prevalent Cases of Peanut Allergy with Concomitant Food Allergy and Other Nut Allergy

Figure 9: 8MM, Probable Diagnosed Prevalent Cases of Peanut Allergy, Men and Women, All Ages, 2017

Figure 10: 8MM, Age-Specific Probable Diagnosed Prevalent Cases of Peanut Allergy, Men and Women, N, 2017

Figure 11: 8MM, Sex-Specific Probable Diagnosed Prevalent Cases of Peanut Allergy, All Ages, N, 2017

Figure 12: 8MM, Probable Diagnosed Prevalent Cases of Peanut Allergy with Comorbid Condition, Men and Women, All Ages, N, 2017

Figure 13: Typical Diagnostic Schemes for Peanut Allergy

Figure 14: Typical Management Scheme for an Individual Diagnosed with Peanut Allergy

Figure 15: Addendum Guidelines for Peanut Allergy Prevention

Figure 16: Global (8MM) Use of Different Branded and Generic Epinephrine Auto-injector Devices, 2017

Figure 17: Rates of Epinephrine Auto-injector Prescription to Peanut Allergy Patients in the 8MM, 2017

Figure 18: Unmet Needs and Opportunities in Peanut Allergy, 2017

Figure 19: Estimated Accessibility to Allergists Throughout the 8MM

Figure 20: Overview of the Development Pipeline in Peanut Allergy, 2017

Figure 21: Key Phase II/III Trials for the Pipeline Agents that GlobalData Expects be Licensed for Peanut Allergy in the 8MM During the Forecast Period, 2017

Figure 22: Competitive Assessment of the Pipeline Drugs Benchmarked Against the SOC, Experimental Peanut OIT, 2017

Figure 23: Global (8MM) Sales Forecast for Peanut Allergy, 2017–2027

Figure 24: Global (8MM) Sales Forecast by Geography for Peanut Allergy in 2017 and 2027

Figure 25: Global (8MM) Sales Forecast by Therapy for Peanut Allergy in 2017 and 2027

Figure 26: Global (8MM) Sales Forecast by Age for Viaskin Peanut and AR-101 in 2027

Figure 27: Sales Forecast by Therapy for Peanut Allergy in the US in 2017 and 2027

Figure 28: Sales Forecast by Therapy for Peanut Allergy in the 5EU in 2017 and 2027

Figure 29: Sales Forecast by Therapy for Peanut Allergy in Canada in 2017 and 2027

Figure 30: Sales Forecast by Therapy for Peanut Allergy in Australia in 2017 and 2027

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports